Man denied vital life saving drug

Health bosses have been accused of putting money before lives after they refused to fund a life-saving treatment needed for a leukaemia patient.

Emmanuel Adjei-Yeboah, from Colliers Wood, south-west London, is facing an uncertain future after the tight-wad bosses of Sutton and Merton Primary Care Trust (PCT) turned down two separate requests for Myelotarg, a treatment that will aid Adjei-Y e b o a h ’ s antibodies while he undergos vital chemotherapy.

According to the African Caribbean Leukaemia Trust (ACLT) Yeboah’s chances of surviving his leukaemia battle will plummet if he is unable to receive the medication.

The 28-year-old’s plight began after he suffered a relapse last December, despite having undergone a bone marrow transplant five months earlier.

Before he can undergo another bone marrow transplant needed to increase his chances of survival, Adjei-Yeboah needs further chemo-therapy treatment to enable him to go into remission. However, the PCT have twice refused to fund the life-saving treatment leaving him in limbo.

Beverley De-Gale and Orin Lewis, who co-founded ACLT, have accused the PCT of putting money before life. They told New Nation: ‘This is an example of the NHS gone mad and putting spreadsheets/cost analysis ahead of an individual’s life.

We totally understand that unfavourable key decisions have to be made, but this one is totally unfair and unreasonable. Emmanuel has spent so much of his healthy spare time aiding us in inspiring so many other people to register as potential Bone Marrow donors.

This is his way of giving back and s aying thank you to the community for coming to his aid when he needed a donor. ‘Decisions like this one will only serve to create more suspicion and doubt about the black community engaging with the established medical services.’

A spokesman for Merton and Sutton PCT justified the decision saying it was made because no exceptional circumstances were demonstrated to show why Adjei-Yeboah could not received the standard treatment, which is already available, he added: ‘Furthermore, Myelotarg is still in the trial stages and is not licenced in the UK.

‘In order to provide a consistent and structured approach to making decisions, the exceptional circumstances panel makes decisions based on a number of guiding principles, including the individual patient’s case, the available clinical evidence for the treatment, the presence of exceptional circumstances and the availability of alternate treatments.’